Home Health Aurinia to cease improvement of immunotherapies after strategic assessment – ET HealthWorld | Pharma

Aurinia to cease improvement of immunotherapies after strategic assessment – ET HealthWorld | Pharma

0
Aurinia to cease improvement of immunotherapies after strategic assessment – ET HealthWorld | Pharma

[ad_1]

Bengaluru: Aurinia Prescribed drugs will cease analysis and improvement on its immunotherapies to concentrate on its kidney illness drug Lupkynis after failing to draw a proper buyout provide, the corporate stated on Thursday.

The Canada-based drugmaker stated it had failed to draw a proper provide after it had launched into a strategic assessment it launched on the finish of June, confirming a Reuters report from earlier within the day.

Aurinia anticipates lowering worker headcount by no less than 25% by the top of the primary quarter of 2024.

The corporate additionally initiated a share repurchase program of as much as $150 million.

  • Printed On Feb 15, 2024 at 06:26 PM IST

Be part of the group of 2M+ business professionals

Subscribe to our publication to get newest insights & evaluation.

Obtain ETHealthworld App

  • Get Realtime updates
  • Save your favorite articles


Scan to obtain App


[ad_2]

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here